Shareholders for Walgreens Boots Alliance overwhelmingly voted to approve the company’s sale to Sycamore Partners, with 96% of shareholders at a special meeting voting to green-light the merger, ...

Dive Brief: Walgreens shareholders overwhelmingly approved the previously announced $10 billion acquisition of the company by private equity firm Sycamore Partners, according to a Friday news ...

The shareholders of Boots' parent company have approved the US group's sale to private equity firm Sycamore Partners, leaving the future unclear for the UK pharmacy giant.

With plans to sell later in 2025 to New York private-equity firm Sycamore Partners, the nation's largest retail pharmacy operator has withdrawn its fiscal 2025 guidance.

Walgreens was in talks to sell itself to Sycamore Partners in December after the company revealed plans to close around 1,200 retail stores in a three-year timeframe, including about 500 closures ...

Walgreens shareholders approve $10B sale to Sycamore Partners. The deal will take the company private and retain its Chicago-area headquarters.

Walgreens shareholders approve $10B sale to Sycamore Partners. The deal will take the company private and retain its Chicago-area headquarters.

By overwhelmingly approving the $10 billion sale to private-equity firm Sycamore Partners, investors set an official end date on Walgreens’ run as one of Chicago’s most iconic public companies ...

Shareholders of Walgreens Boots Alliance overwhelmingly approved the drugstore chain's $10 billion acquisition by private equity firm Sycamore. It is a rough era for national pharmacy chains like ...

Walgreens Boots Alliance shareholders have overwhelmingly approved the company’s pending acquisition by Sycamore Partners. According to preliminary results, approximately 96% of votes cast at ...

(Reuters) -Walgreens Boots Alliance, which is being taken private by Sycamore Partners, beat analysts' estimates for third-quarter profit on Thursday, helped by cost-cutting measures such as store ...

Walgreens said overall third-quarter sales were up 7.2% vs. a year ago, to $39 billion, which reflected the growth in U.S. pharmacy sales and growth in its international business.